Alterity Therapeutics Limited (ATHE) 6-K 28 Feb 22 2022 Q2 Results for announcement to the market Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Dec. 31, 2021
Document Information Line Items
Entity Registrant Name	ALTERITY THERAPEUTICS LTD
Document Type	6-K
Current Fiscal Year End Date	--06-30
Amendment Flag	false
Entity Central Index Key	0001131343
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity File Number	000-49843

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income
Interest income	$ 1,350	$ 6,553
Other income	2,359,198	1,924,389
Expenses
Intellectual property expenses	(205,896)	(160,304)
General and administration expenses	(3,194,790)	(3,673,407)
Research and development expenses	(6,761,542)	(5,806,841)
Other operating expenses	(624)	(20)
Other gains/(losses)	1,218,745	(852,232)
Loss for the period	(6,583,559)	(8,561,862)
Loss before income tax	(6,583,559)	(8,561,862)
Income tax expense
Other comprehensive loss
Other comprehensive income for the period, net of tax
Total comprehensive loss for the period	$ (6,583,559)	$ (8,561,862)
Loss per share for profit attributable to the ordinary equity holders of the Group:
Basic loss per share (in Dollars per share)	$ (0.27)	$ (0.65)
Diluted loss per share (in Dollars per share)	$ (0.27)	$ (0.65)

Consolidated Statement of Finan

Consolidated Statement of Financial Position (Unaudited) - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 37,002,201	$ 28,115,516
Trade and other receivables	6,260,577	4,277,677
Other current assets	1,599,963	1,095,753
Total current assets	44,862,741	33,488,946
Non-current assets
Property, plant and equipment	27,270	31,313
Right-of-use assets	41,039	65,495
Total non-current assets	68,309	96,808
Total assets	44,931,050	33,585,754
Current liabilities
Trade and other payables	3,134,160	2,502,509
Provisions	613,098	537,368
Other current liabilities	15,167	27,746
Total current liabilities	3,762,425	3,067,623
Non-current liabilities
Provisions	12,907	9,768
Other non-current liabilities	26,727	37,903
Total non-current liabilities	39,634	47,671
Total liabilities	3,802,059	3,115,294
Net assets	41,128,991	30,470,460
EQUITY
Contributed equity	213,814,776	197,447,990
Reserves	3,626,188	2,750,884
Accumulated losses	(176,311,973)	(169,728,414)
Total equity	$ 41,128,991	$ 30,470,460

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity (Unaudited) - AUD ($)	Contributed equity	Reserves	Accumulated losses	Total
Balance at Jun. 30, 2020	$ 160,703,754	$ 866,121	$ (154,419,061)	$ 7,150,814
Loss for the period			(8,561,862)	(8,561,862)
Total comprehensive income for the period			(8,561,862)	(8,561,862)
Transactions with owners in their capacity as owners:
Issue of ordinary shares	36,562,055			36,562,055
Share-based payment expenses		1,577,720		1,577,720
Transaction costs	(2,372,505)			(2,372,505)
Total transactions with owners in their capacity as owners	34,189,550	1,577,720		35,767,270
Balance at Dec. 30, 2020	194,893,304	2,443,841	(162,980,923)	34,356,222
Balance at Jun. 30, 2021	197,447,990	2,750,884	(169,728,414)	30,470,460
Total comprehensive income for the period				(6,583,559)
Balance at Dec. 31, 2021				41,128,991
Balance at Jun. 30, 2021	197,447,990	2,750,884	(169,728,414)	30,470,460
Loss for the period			(6,583,559)	(6,583,559)
Total comprehensive income for the period			(6,583,559)	(6,583,559)
Transactions with owners in their capacity as owners:
Issue of ordinary shares	17,176,040			17,176,040
Share-based payment expenses		875,304		875,304
Transaction costs	(809,254)			(809,254)
Total transactions with owners in their capacity as owners	16,366,786	875,304		17,242,090
Balance at Dec. 30, 2021	$ 213,814,776	$ 3,626,188	$ (176,311,973)	$ 41,128,991

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Payments to suppliers and employees	$ (9,002,490)	$ (7,385,267)
COVID-19 government relief	103,338	53,564
Other grant received	225,746
Interest received	1,352	1,397
Net cash (outflow) from operating activities	(8,672,054)	(7,330,306)
Cash flows from investing activities
Payments for property, plant and equipment	(2,559)	(2,494)
Net cash (outflow) from investing activities	(2,559)	(2,494)
Cash flows from financing activities
Proceeds from issues of shares and other equity securities	17,176,040	36,562,055
Transaction costs relating to issue of equity	(809,254)	(2,372,505)
Principle elements of lease payments	(23,755)	(24,249)
Net cash inflow from financing activities	16,343,031	34,165,301
Net increase in cash and cash equivalents	7,668,418	26,832,501
Cash and cash equivalents at the beginning of the financial year	28,115,516	9,196,892
Effects of exchange rate changes on cash and cash equivalents	1,218,267	(987,215)
Cash and cash equivalents at end of period	$ 37,002,201	$ 35,042,178

Basis of Preparation of Half-Ye

Basis of Preparation of Half-Year Report	6 Months Ended
	Dec. 31, 2021
Disclosure Of background and significant accounting policies [Abstract]
Basis of preparation of half-year report	1 Basis of preparation of half-year report This condensed consolidated interim report for the half-year reporting period ended 31 December 2021 has been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting Corporations Act 2001. This condensed consolidated interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made by Alterity Therapeutics Limited (the “Group”) during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period except as discussed below. (a) New and amended standards adopted by the Group The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ‘AASB’ that are mandatory for the current reporting period. The adoption of these standards has not had any impact on the disclosures or amounts reported in these financial statements.

Significant Changes in The Curr

Significant Changes in The Current Reporting Period	6 Months Ended
	Dec. 31, 2021
Significant Changes In Current Reporting Period [Abstract]
Significant changes in the current reporting period	2 Significant changes in the current reporting period In July 2021, the Group raised A$17,176,040 by issuing 322,857,900 shares at $0.0532 per share through the use of its “at-the-market” (ATM) facility to fund working capital and progress its research and development activities. There have been no other significant changes in the state of affairs of the Company during the period.

Segment Information

Segment Information	6 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment information	3 Segment information Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited. For the current and previous reporting periods, the Group operated in one segment, being research and development in the field of Parkinsonian and other neurodegenerative disorders.

Dividends

Dividends	6 Months Ended
	Dec. 31, 2021
Dividends [Abstract]
Dividends	4 Dividends The Group has not declared any dividends in the period ended 31 December 2021 (2020: nil

Loss Per Share

Loss Per Share	6 Months Ended
	Dec. 31, 2021
Earnings per share [abstract]
Loss per share	5 Loss per share (a) Basic and diluted loss per share 31 December 31 December 2021 2020 Loss per share for profit attributable to the ordinary equity holders of the Group: Basic loss per share (0.27 ) (0.65 ) Diluted loss per share (0.27 ) (0.65 ) (b) Reconciliation of loss used in calculating loss per share 31 December 31 December 2021 2020 Basic loss per share Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share: (6,583,559 ) (8,561,862 ) Diluted loss per share Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share: (6,583,559 ) (8,561,862 ) (c) Weighted average number of shares used as the denominator 31 December 31 December Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 2,405,110,327 1,323,432,372 Options that are considered to be potential ordinary shares are excluded from the weighted average number of ordinary shares used in the calculation of basic loss per share. Where dilutive, potential ordinary shares are included in the calculation of diluted loss per share. All the options on issue do not have the effect to dilute the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share.

Interest and Other Income

Interest and Other Income	6 Months Ended
	Dec. 31, 2021
Interest and Other Income [Abstract]
Interest and other income	6 Interest and other income 31 December 31 December 2021 2020 Interest and other income Interest income 1,350 6,553 1,350 6,553 Other Income R&D tax incentive 2,133,452 1,883,325 COVID-19 relief - 41,064 Other grant (1) 225,746 - 2,359,198 1,924,389 1 Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

Loss for the Period

Loss for the Period	6 Months Ended
	Dec. 31, 2021
Loss for the Period [Abstract]
Loss for the period	7 Loss for the period 31 December 31 December 2021 2020 Loss before income tax has been determined after: General and administration expenses Depreciation on fixed assets 6,602 12,417 Depreciation on leased assets 24,934 23,215 Employee expenses (non R&D related) 370,564 376,220 Consultant and director expenses 242,563 387,310 Audit, internal control and other assurance expenses 109,398 115,798 Corporate compliance expenses 217,776 372,697 Office rental 30,458 66,664 Other administrative and office expenses 503,885 332,784 Insurance expenses 324,798 258,582 Share-based payment expenses 875,304 1,577,720 Corporate advisory 488,508 150,000 3,194,790 3,673,407 Research and development expenses Employee expenses 1,192,238 1,072,468 Other research and development expenses 1 5,569,304 4,734,373 6,761,542 5,806,841 Other gains and losses Foreign exchange (gain)/ loss (1,218,745 ) 852,232 (1,218,745 ) 852,232 (1) Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.

Financial Assets and Financial

Financial Assets and Financial Liabilities	6 Months Ended
	Dec. 31, 2021
Financial Assets and Financial Liabilities [Abstract]
Financial assets and financial liabilities	8 Financial assets and financial liabilities (a) Trade and other receivables 31 December 30 June Current Non- Total Current Non- Total A$ A$ A$ A$ A$ A$ R&D tax incentive receivable 6,259,819 - 6,259,819 4,126,364 - 4,126,364 Accrued interest income 267 - 267 269 - 269 Goods and services tax receivable 491 - 491 47,706 - 47,706 Other receivable - - - 103,338 - 103,338 6,260,577 - 6,260,577 4,277,677 - 4,277,677 R&D tax incentive receivable represents the amount of R&D tax incentive the Group expects to recover. For further details, see note 13(a). A 43.5% R&D Tax incentive refundable tax offset is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the year ended 30 June 2021 and half-year ended 31 December 2021, the Group recorded $4,126,364 and $2,133,722 respectively in other income and receivables. (i) Classification as trade and other receivables Trade receivables and other receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. If collection of the amounts is expected in one year or less they are classified as current assets. If not, they are presented as non-current assets. Trade and other receivables are generally due for settlement within one year and therefore are all classified as current. (b) Recognised fair value measurements The financial instruments recognised at fair value in the statement of financial position have been analysed and classified using a fair value hierarchy reflecting the significance of the inputs used in making the measurements. The fair value hierarchy consists of the following levels: ● quoted prices in active markets for identical assets or liabilities (Level 1); ● inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices) (Level 2); and ● inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level3). During the period, none of the Group’s assets and liabilities had their fair value determined using the fair value hierarchy. No transfers between the levels of the fair value hierarchy occurred during the current or previous periods.

Equity

Equity	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Equity	9 Equity (a) Contributed equity 31 December 30 June 31 December 30 June Ordinary shares - fully paid 2,406,874,578 2,084,016,678 213,814,776 197,447,990 Movements in ordinary share: Details Number of shares A$ Opening balance 1 July 2021 2,084,016,678 197,447,990 Shares issued during the year 322,857,900 17,176,040 Transaction costs - (809,254 ) Balance 31 December 2021 2,406,874,578 213,814,776 Details of shares issued during the current period: Issue price Amount Details Number A$ A$ 2-Jul-2021 Issue of shares under ATM facility 322,857,900 0.0532 17,176,040 322,857,900 17,176,040 (b) Accumulated losses Movements in accumulated losses were as follows: 31 December 31 December Balance at the beginning of the period 169,728,414 154,419,061 Net loss for the period 6,583,559 8,561,862 Balance at the end of the period 176,311,973 162,980,923 (c) Reserves (i) Options 31 December 30 June 31 December 30 June Options over fully paid ordinary shares 205,692,720 160,542,720 3,626,188 2,750,884 The table below presents the movements in options granted and issued during the half-year ended 31 December 2021. Details Number Amount 8-Dec-2021 Unlisted options issued to consultant 12,000,000 326,544 8-Dec-2021 Unlisted options issued to employees 13,900,000 13,326 8-Dec-2021 Unlisted options issued to employees 19,250,000 18,816 45,150,000 358,686 Date issued Quantity Grant Date Expiry Date Exercise price ($) date per option ($) * 08-Dec-2021 12,000,000 31-Jul-2021 31-Jul-2024 $ 0.0700 $ 0.0272 08-Dec-2021 13,900,000 29-Nov-2021 29-Nov-2026 $ 0.0238 $ 0.0210 08-Dec-2021 19,250,000 29-Nov-2021 29-Nov-2026 $ 0.0375 $ 0.0214 45,150,000 * Rounded to the nearest four decimal points. (ii) Free-attaching options 31 December 30 June 31 December 30 June Free-attaching options 674,694,939 674,694,939 - - There was no movement during the half-year ended 31 December 2021. There have been no other options over fully paid ordinary shares issued, exercised or forfeited during the current period. (iii) Nature and purpose of reserves The share-based payments reserve is used to recognise the fair value of options issued to employees and consultants but not exercised.

Reconciliation of Profit After

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities	6 Months Ended
	Dec. 31, 2021
Reconciliation of profit after income tax to net cash flow from operating activities [Abstract]
Reconciliation of profit after income tax to net cash flow from operating activities	10 Reconciliation of profit after income tax to net cash flow from operating activities 31 December 31 December Loss for the period 6,583,559 8,561,862 Depreciation on fixed assets (6,602 ) (12,417 ) Depreciation on leased assets (24,934 ) (23,215 ) Non-cash employee benefits expense - share-based payments (875,304 ) (1,577,720 ) Net foreign exchange differences 1,218,745 (987,215 ) (Increase)/decrease in provisions (78,869 ) (62,547 ) Increase/(decrease) in trade and other receivables 1,982,900 1,916,120 Increase/(decrease) in other current assets 504,210 (229,445 ) (Increase)/decrease in trade and other payables (631,651 ) (255,505 ) (Increase)/decrease in other current liabilities - 388 8,672,054 7,330,306

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2021
Related party transactions [Abstract]
Related party transactions	11 Related party transactions During the half-year ended 31 December 2021 the Group paid a total of A$37,500 (excl. GST) in corporate advisory fees to Montoya Pty Ltd, an associated entity of Mr. Lawrence Gozlan, a director of the Group and A$101,400 (excl. GST) in corporate advisory fees to Kemdev Pty Ltd, an associated entity of Mr. Geoffrey Kempler. A$75,000 (excl. GST) is payable to Kemdev Pty Ltd at the end of the period. There were no other related party transactions other than those related to director and key management personnel remuneration and equity and transactions by the Group and its subsidiaries.

Events Occurring After the Repo

Events Occurring After the Reporting Period	6 Months Ended
	Dec. 31, 2021
Events Occurring after the Reporting Period [Abstract]
Events occurring after the reporting period	12 Events occurring after the reporting period Resignation of Non-Executive Directors On 4 January 2022 Dr. David Sinclair and Mr. Tristan Edwards resigned as Non-Executive Directors of the Group. Options issued under the ESOP Plan to Dr. Sinclair (7,000,000) and Mr. Edwards (7,000,000) as approved in September 2020 were forfeited and cancelled upon resignation. No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial periods.

Significant Estimates and Assum

Significant Estimates and Assumptions	6 Months Ended
	Dec. 31, 2021
Significant Estimates and Assumptions [Abstract]
Significant estimates and assumptions	13 Significant estimates and assumptions Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances. The Company and its two wholly-owned subsidiaries (the “Group”) makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period are discussed below. The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period. (a) R&D tax incentives The Australian Government replaced the research and development tax concession with the research and development tax incentive from 1 July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the period to 31 December 2021 the Group has recorded an item in other income of $A2,133,452 (31 Dec 2020: $1,883,325) to recognise this amount which relates to this period. On 7 October 2020, the Treasury Laws Amendment (A Tax Plan for the Covid-19 Economic Recovery Bill 2020) was introduced to the Parliament. This legislation supersedes the Treasury Laws Amendment (Research and Development Incentive) Bill 2019. Under the amendments, commencing 1 July 2021, the refundable tax offset rate for companies with aggregated turnover below $20 million would become 18.5% above the companies tax rate and the R&D expenditure threshold would be increased from $100 million to $150 million. Management does not consider the rate reduction or the refund cap has material impact towards the Group’s R&D tax incentive claim for the next financial year going forward. The rate reduction has no material impact on the R&D tax incentive estimate reported in financial statements for the half-year ended 31 December 2021.

Covid-19 Impact on Business

Covid-19 Impact on Business	6 Months Ended
	Dec. 31, 2021
Covid-19 Impact on Business [Abstract]
COVID-19 impact on business	14 COVID-19 impact on business The COVID-19 pandemic has caused uncertainty in global markets and its impact is unable to be reliably measured. However, COVID-19 has had limited effect thus far on the Group’s operation. Development activities have continued with minimal disruption.

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2021
Disclosure of earnings per share [text block] [Abstract]
Schedule of earning loss per share	31 December 31 December 2021 2020 Loss per share for profit attributable to the ordinary equity holders of the Group: Basic loss per share (0.27 ) (0.65 ) Diluted loss per share (0.27 ) (0.65 ) 31 December 31 December 2021 2020 Basic loss per share Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share: (6,583,559 ) (8,561,862 ) Diluted loss per share Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share: (6,583,559 ) (8,561,862 ) 31 December 31 December Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 2,405,110,327 1,323,432,372

Interest and Other Income (Tabl

Interest and Other Income (Tables)	6 Months Ended
	Dec. 31, 2021
Interest and Other Income [Abstract]
Schedule of interest and other income	31 December 31 December 2021 2020 Interest and other income Interest income 1,350 6,553 1,350 6,553 Other Income R&D tax incentive 2,133,452 1,883,325 COVID-19 relief - 41,064 Other grant (1) 225,746 - 2,359,198 1,924,389 1 Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

Loss for the Period (Tables)

Loss for the Period (Tables)	6 Months Ended
	Dec. 31, 2021
Loss for the Period [Abstract]
Schedule of loss for the period	31 December 31 December 2021 2020 Loss before income tax has been determined after: General and administration expenses Depreciation on fixed assets 6,602 12,417 Depreciation on leased assets 24,934 23,215 Employee expenses (non R&D related) 370,564 376,220 Consultant and director expenses 242,563 387,310 Audit, internal control and other assurance expenses 109,398 115,798 Corporate compliance expenses 217,776 372,697 Office rental 30,458 66,664 Other administrative and office expenses 503,885 332,784 Insurance expenses 324,798 258,582 Share-based payment expenses 875,304 1,577,720 Corporate advisory 488,508 150,000 3,194,790 3,673,407 Research and development expenses Employee expenses 1,192,238 1,072,468 Other research and development expenses 1 5,569,304 4,734,373 6,761,542 5,806,841 Other gains and losses Foreign exchange (gain)/ loss (1,218,745 ) 852,232 (1,218,745 ) 852,232

Financial Assets and Financia_2

Financial Assets and Financial Liabilities (Tables)	6 Months Ended
	Dec. 31, 2021
Financial Assets and Financial Liabilities [Abstract]
Schedule of trade and other receivables	31 December 30 June Current Non- Total Current Non- Total A$ A$ A$ A$ A$ A$ R&D tax incentive receivable 6,259,819 - 6,259,819 4,126,364 - 4,126,364 Accrued interest income 267 - 267 269 - 269 Goods and services tax receivable 491 - 491 47,706 - 47,706 Other receivable - - - 103,338 - 103,338 6,260,577 - 6,260,577 4,277,677 - 4,277,677

Equity (Tables)

Equity (Tables)	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of contributed equity	31 December 30 June 31 December 30 June Ordinary shares - fully paid 2,406,874,578 2,084,016,678 213,814,776 197,447,990
Schedule of movements in ordinary share	Details Number of shares A$ Opening balance 1 July 2021 2,084,016,678 197,447,990 Shares issued during the year 322,857,900 17,176,040 Transaction costs - (809,254 ) Balance 31 December 2021 2,406,874,578 213,814,776
Schedule of details of shares issued during the current period	Issue price Amount Details Number A$ A$ 2-Jul-2021 Issue of shares under ATM facility 322,857,900 0.0532 17,176,040 322,857,900 17,176,040
Schedule of movements in accumulated losses	31 December 31 December Balance at the beginning of the period 169,728,414 154,419,061 Net loss for the period 6,583,559 8,561,862 Balance at the end of the period 176,311,973 162,980,923
Schedule of options	31 December 30 June 31 December 30 June Options over fully paid ordinary shares 205,692,720 160,542,720 3,626,188 2,750,884
Schedule of presents the movements in options granted and issued	Details Number Amount 8-Dec-2021 Unlisted options issued to consultant 12,000,000 326,544 8-Dec-2021 Unlisted options issued to employees 13,900,000 13,326 8-Dec-2021 Unlisted options issued to employees 19,250,000 18,816 45,150,000 358,686
Schedule of fair value at grant date per option	Date issued Quantity Grant Date Expiry Date Exercise price ($) date per option ($) * 08-Dec-2021 12,000,000 31-Jul-2021 31-Jul-2024 $ 0.0700 $ 0.0272 08-Dec-2021 13,900,000 29-Nov-2021 29-Nov-2026 $ 0.0238 $ 0.0210 08-Dec-2021 19,250,000 29-Nov-2021 29-Nov-2026 $ 0.0375 $ 0.0214 45,150,000
Schedule of options free-attaching options	31 December 30 June 31 December 30 June Free-attaching options 674,694,939 674,694,939 - -

Reconciliation of Profit Afte_2

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables)	6 Months Ended
	Dec. 31, 2021
Disclosure of profit (loss) from operating activities [text block] [Abstract]
Schedule of profit after income tax to net cash flow from operating activities	31 December 31 December Loss for the period 6,583,559 8,561,862 Depreciation on fixed assets (6,602 ) (12,417 ) Depreciation on leased assets (24,934 ) (23,215 ) Non-cash employee benefits expense - share-based payments (875,304 ) (1,577,720 ) Net foreign exchange differences 1,218,745 (987,215 ) (Increase)/decrease in provisions (78,869 ) (62,547 ) Increase/(decrease) in trade and other receivables 1,982,900 1,916,120 Increase/(decrease) in other current assets 504,210 (229,445 ) (Increase)/decrease in trade and other payables (631,651 ) (255,505 ) (Increase)/decrease in other current liabilities - 388 8,672,054 7,330,306

Significant Changes in The Cu_2

Significant Changes in The Current Reporting Period (Details)	1 Months Ended
	Jul. 31, 2021AUD ($)$ / sharesshares
Significant Changes In Current Reporting Period [Abstract]
Company issued amount | $	$ 17,176,040
Number Of Shares Issued | shares	322,857,900
Price per share | $ / shares	$ 0.0532

Dividends (Details)

Dividends (Details) - USD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Dividends [Abstract]
Dividends

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of earning loss per share - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Loss per share for profit attributable to the ordinary equity holders of the Group:
Basic loss per share	$ (0.27)	$ (0.65)
Diluted loss per share	$ (0.27)	$ (0.65)
Basic loss per share
Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share:	$ (6,583,559)	$ (8,561,862)
Diluted loss per share
Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share:	$ (6,583,559)	$ (8,561,862)
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	2,405,110,327	1,323,432,372

Interest and Other Income (Deta

Interest and Other Income (Details) - Schedule of interest and other income - AUD ($)		6 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Interest and other income
Interest income		$ 1,350	$ 6,553
Total		1,350	6,553
Other Income
R&D tax incentive		2,133,452	1,883,325
COVID-19 relief			41,064
Other grant	[1]	225,746
Total		$ 2,359,198	$ 1,924,389
[1]	Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

Loss for the Period (Details) -

Loss for the Period (Details) - Schedule of loss for the period - AUD ($)		6 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
General and administration expenses
Depreciation on fixed assets		$ 6,602	$ 12,417
Depreciation on leased assets		24,934	23,215
Employee expenses (non R&D related)		370,564	376,220
Consultant and director expenses		242,563	387,310
Audit, internal control and other assurance expenses		109,398	115,798
Corporate compliance expenses		217,776	372,697
Office rental		30,458	66,664
Other administrative and office expenses		503,885	332,784
Insurance expenses		324,798	258,582
Share-based payment expenses		875,304	1,577,720
Corporate advisory		488,508	150,000
Total general and administration expense		3,194,790	3,673,407
Research and development expenses
Employee expenses		1,192,238	1,072,468
Other research and development expenses	[1]	5,569,304	4,734,373
Total research and development expenses		6,761,542	5,806,841
Other gains and losses
Foreign exchange (gain)/ loss		(1,218,745)	852,232
Loss for the period		$ (1,218,745)	$ 852,232
[1]	Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.

Financial Assets and Financia_3

Financial Assets and Financial Liabilities (Details)	6 Months Ended
	Dec. 31, 2021AUD ($)
Disclosure of financial instruments [text block] [Abstract]
R&D tax incentive percentage	43.50%
Company annual aggregate turnover	$ 20,000,000
Other income	4,126,364
Other receivables	$ 2,133,722

Financial Assets and Financia_4

Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of trade and other receivables [Abstract]
R&D tax incentive receivable, Current	$ 6,259,819	$ 4,126,364
R&D tax incentive receivable, Non-current
R&D tax incentive receivable, Total	6,259,819	4,126,364
Accrued interest income, Current	267	269
Accrued interest income, Non-current
Accrued interest income, Total	267	269
Goods and services tax receivable, Current	491	47,706
Goods and services tax receivable, Non-current
Goods and services tax receivable, Total	491	47,706
Other receivable, Current		103,338
Other receivable, Non-current
Other receivable, Total		103,338
Trade and other receivables, Current	6,260,577	4,277,677
Trade and other receivables, Non-current
Trade and other receivables, Total	$ 6,260,577	$ 4,277,677

Equity (Details) - Schedule of

Equity (Details) - Schedule of contributed equity - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of contributed equity [Abstract]
Ordinary shares - fully paid, shares	2,406,874,578	2,084,016,678
Ordinary shares - fully paid value	$ 213,814,776	$ 197,447,990

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of movements in ordinary share	6 Months Ended
	Dec. 31, 2021AUD ($)shares
Schedule of movements in ordinary share [Abstract]
Opening balance, shares | shares	2,084,016,678
Opening balance | $	$ 197,447,990
Shares issued during the year, shares | shares	322,857,900
Shares issued during the year | $	$ 17,176,040
Transaction costs, shares | shares
Transaction costs | $ | $	$ (809,254)
Ending balance, shares | shares	2,406,874,578
Ending balance | $	$ 213,814,776

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of details of shares issued during the current period	Jul. 02, 2021AUD ($)$ / sharesshares
Schedule of details of shares issued during the current period [Abstract]
Number Issue of shares under ATM facility | shares	322,857,900
Issue price Issue of shares under ATM facility | $ / shares	$ 0.0532
Amount Issue of shares under ATM facility | $	$ 17,176,040
Total number of shares issued | shares	322,857,900
Total value of shares issued | $	$ 17,176,040

Equity (Details) - Schedule o_4

Equity (Details) - Schedule of movements in accumulated losses - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of movements in accumulated losses [Abstract]
Balance at the beginning of the period	$ 169,728,414	$ 154,419,061
Net loss for the period	6,583,559	8,561,862
Balance at the end of the period	$ 176,311,973	$ 162,980,923

Equity (Details) - Schedule o_5

Equity (Details) - Schedule of options - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of options [Abstract]
Options over fully paid ordinary shares, shares	205,692,720	160,542,720
Options over fully paid ordinary shares, value	$ 3,626,188	$ 2,750,884

Equity (Details) - Schedule o_6

Equity (Details) - Schedule of presents the movements in options granted and issued	6 Months Ended
	Dec. 31, 2021AUD ($)shares
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Number of stock option shares issued | shares	45,150,000
Stock option shares issued value | $	$ 358,686
Unlisted options issued to consultant [Member]
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Issued Date	Dec. 8, 2021
Number of stock option shares issued | shares	12,000,000
Stock option shares issued value | $	$ 326,544
Unlisted options issued to employees [Member]
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Issued Date	Dec. 8, 2021
Number of stock option shares issued | shares	13,900,000
Stock option shares issued value | $	$ 13,326
Unlisted options issued to employees [Member[
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Issued Date	Dec. 8, 2021
Number of stock option shares issued | shares	19,250,000
Stock option shares issued value | $	$ 18,816

Equity (Details) - Schedule o_7

Equity (Details) - Schedule of fair value at grant date per option	6 Months Ended
	Dec. 31, 2021$ / sharesshares
Equity (Details) - Schedule of fair value at grant date per option [Line Items]
Quantity | shares	45,150,000
Date Issued One [Member]
Equity (Details) - Schedule of fair value at grant date per option [Line Items]
Date issued	Dec. 8, 2021
Quantity | shares	12,000,000
Grant Date	31-Jul-2021
Expiry Date	31-Jul-2024
Exercise price	$ 0.07
Fair value at grant date per option	$ 0.0272	[1]
Date Issued Two [Member]
Equity (Details) - Schedule of fair value at grant date per option [Line Items]
Date issued	Dec. 8, 2021
Quantity | shares	13,900,000
Grant Date	29-Nov-2021
Expiry Date	29-Nov-2026
Exercise price	$ 0.0238
Fair value at grant date per option	$ 0.021	[1]
Date Issued Three [Member]
Equity (Details) - Schedule of fair value at grant date per option [Line Items]
Date issued	Dec. 8, 2021
Quantity | shares	19,250,000
Grant Date	29-Nov-2021
Expiry Date	29-Nov-2026
Exercise price	$ 0.0375
Fair value at grant date per option	$ 0.0214	[1]
[1]	Rounded to the nearest four decimal points.

Equity (Details) - Schedule o_8

Equity (Details) - Schedule of options free-attaching options - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of options free-attaching options [Abstract]
Free-attaching options, shares	674,694,939	674,694,939
Free-attaching options, value

Reconciliation of Profit Afte_3

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of profit after income tax to net cash flow from operating activities [Abstract]
Loss for the period	$ 6,583,559	$ 8,561,862
Depreciation on fixed assets	(6,602)	(12,417)
Depreciation on leased assets	(24,934)	(23,215)
Non-cash employee benefits expense - share-based payments	(875,304)	(1,577,720)
Net foreign exchange differences	1,218,745	(987,215)
(Increase)/decrease in provisions	(78,869)	(62,547)
Increase/(decrease) in trade and other receivables	1,982,900	1,916,120
Increase/(decrease) in other current assets	504,210	(229,445)
(Increase)/decrease in trade and other payables	(631,651)	(255,505)
(Increase)/decrease in other current liabilities		388
Net cash flows used in operating activities	$ 8,672,054	$ 7,330,306

Related Party Transactions (Det

Related Party Transactions (Details)	6 Months Ended
	Dec. 31, 2021AUD ($)
Related Party Transactions (Details) [Line Items]
Advisory fees paid	$ 37,500
Lawrence Gozlan [Member]
Related Party Transactions (Details) [Line Items]
Advisory fees paid	101,400
Geoffrey Kempler [Member]
Related Party Transactions (Details) [Line Items]
Advisory fees paid	$ 75,000

Events Occurring After the Re_2

Events Occurring After the Reporting Period (Details)	1 Months Ended
	Sep. 30, 2020shares
Dr Sinclair [Member]
Events Occurring After the Reporting Period (Details) [Line Items]
Forfeited and cancelled	(7,000,000)
Mr Edwards [Member]
Events Occurring After the Reporting Period (Details) [Line Items]
Forfeited and cancelled	(7,000,000)

Significant Estimates and Ass_2

Significant Estimates and Assumptions (Details) - AUD ($)	Jul. 02, 2021	Dec. 31, 2021	Dec. 31, 2020
Significant Estimates and Assumptions (Details) [Line Items]
Research and development, description		The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme.
Description of other income		the Group has recorded an item in other income of $A2,133,452
Other income recognise amount			$ 1,883,325
Refundable tax offset rate value	$ 20,000,000
Refundable tax offset rate	18.50%
Bottom of range [member]
Significant Estimates and Assumptions (Details) [Line Items]
Research and development expenditure	$ 100,000,000
Top of range [member]
Significant Estimates and Assumptions (Details) [Line Items]
Research and development expenditure	$ 150,000,000